TargetMol

Epidermal Growth Factor Receptor Peptide Acetate

Product Code:
 
TAR-T21723L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21723L-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-2mg2mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-5mg5mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-10mg10mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-25mg25mg£300.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-1mL1 mL * 10 mM (in DMSO)£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-50mg50mg£415.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21723L-100mg100mg£581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Epidermal Growth Factor Receptor Peptide exists on the cell surface and is activated by the binding of its specific ligands.EGFR belongs to the ErbB family of receptor tyrosine kinases (RTK).
CAS:
T21723L
Formula:
C63H97N13O25
Molecular Weight:
1436.52
Purity:
0.9881
SMILES:
O=C(N)CC[C@@H](C(O)=O)NC([C@H]1N(C([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](CC(O)=O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O.CC(O)=O

References

1. Yan.?L, Beckman RA (October 2005). "Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development".?BioTechniques?39?(4): 565?8.